Research in context**Evidence before this study**Before this meta-analysis, the evidence available from randomised trials on the effects of statin therapy in older people had been summarised only in meta-analyses of aggregated data from published reports. We searched MEDLINE, Embase, and PubMed for English-language publications published between Jan 1, 1996, and Dec 31, 2017, using the search terms "statins OR HMG CoA Reductase Inhibitors" and "Elderly OR Aged", and found 14 meta-analyses with conflicting assessments of efficacy among older people (generally defined as \>65 years). Because of a lack of access to the individual participant data, none of these previous meta-analyses were able to examine the effects of statins within particular older age groups (eg, \>75 years) in primary and secondary prevention. We previously reported meta-analyses of the effects of statins by age, but these analyses were restricted in scope and some large randomised trials that included older individuals have been reported since they were published.**Added value of this study**We analysed individual participant data from 27 randomised controlled trials (n=174 149) and detailed summary data from one trial (n=12 705). During 4·9 years of follow-up, major vascular events were significantly reduced by statin therapy among all age groups by about a fifth per 1·0 mmol/L LDL cholesterol reduction, including among the 14 483 participants who were older than 75 years at randomisation. Older age groups were disproportionately represented in heart failure and dialysis trials (which did not show an overall benefit with statin therapy), and exclusion of those trials weakened an apparent trend with increasing age towards smaller relative risk reductions in vascular event and mortality outcomes. We found significant reductions in major coronary events in all age groups (including those older than 75 years at randomisation), but the trend towards smaller relative reductions with increasing age persisted, even after excluding heart failure and dialysis trials. However, as the absolute risk of these events was higher in older people, the absolute benefits were similar to, if not greater than, those at younger ages. We observed significant efficacy regardless of age among participants with previous vascular disease, whereas there was a weak trend towards smaller relative risk reductions with increasing age in the primary prevention setting (although there were too few such older participants for reliable assessment in that group alone). Despite previous concerns, we found no adverse effects on cancer or non-vascular mortality in any age group.**Implications of all the available evidence**Statins reduced vascular events irrespective of age, including in people older than 75 years. In the primary prevention setting, among people older than 75 years, there is less evidence of the effects of statin therapy. Ongoing trials are investigating this group directly.

Introduction {#cesec10}
============

Meta-analyses of individual participant data from 27 randomised trials in the Cholesterol Treatment Trialists\' (CTT) Collaboration database indicate that each 1·0 mmol/L reduction in LDL cholesterol with statin therapy reduces the risk of major vascular events by about a fifth, with similar proportional risk reductions among men and women,[@bib1] and across different levels of absolute risk.[@bib2] However, even among patients with established cardiovascular disease, rates of use of statin therapy have been shown to decline with increasing age, and are substantially lower in people older than 75 years, reflecting differences in both prescribing and compliance.[@bib3], [@bib4] This decline is even more prominent among older patients with no evidence of occlusive vascular disease.[@bib5] One explanation for this observation might relate to uncertainty about applying the evidence for statin efficacy and safety from randomised trials to an older population, given that a relatively small number of people aged over 75 years were enrolled in such trials, and many older people have non-cardiovascular comorbidities.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10] The CTT collaboration has age-specific data on vascular events, cause-specific mortality, and cancer from 28 randomised controlled trials of statin therapy among a total of nearly 187 000 participants, of whom about 14 500 were older than 75 years at baseline. We aimed to do a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages and explore the effects of statin therapy among older individuals.

Methods {#cesec20}
=======

Study design and outcomes {#cesec30}
-------------------------

The methods of the CTT Collaboration have been described previously,[@bib11] and were agreed before the reporting of any individual trial results. Randomised trials were eligible for inclusion if the main effect of at least one of the trial interventions was to lower LDL cholesterol, the trial was unconfounded with respect to this intervention (ie, no other differences in modification of risk factors between the relevant treatment groups were intended), and the trial aimed to recruit 1000 or more participants with a scheduled treatment duration of at least 2 years.[@bib11]

As for all CTT analyses,[@bib1], [@bib2], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] the risk of bias was low because of prespecified study methods, the ability to adjust for heterogeneity by weighting rate ratios (RRs) according to trial-level absolute differences in LDL cholesterol, and the low probability of publication bias due to a prospective design with prespecified study eligibility. Prespecified outcomes included major coronary events (defined as non-fatal myocardial infarction or coronary death), coronary revascularisation (angioplasty or bypass grafting), stroke (subdivided by type), site-specific cancers, and cause-specific mortality. Subsequently, we defined major vascular events as the composite of major coronary events, coronary revascularisation, and stroke.

Statistical analysis {#cesec40}
--------------------

Prespecified subgroup analyses included comparisons of the effects of statin therapy among people aged 65 years and younger and people older than 65 years at randomisation (along with several other subgroupings, including by history of vascular disease[@bib11]). However, for the present more detailed analysis, we compared effects between six age groups (55 years or younger, 56--60 years, 61--65 years, 66--70 years, 71--75 years, and older than 75 years) and, where statistical power was limited because of low numbers of specific event types, between two retrospectively defined groups (≤75 years and \>75 years). Because of disproportionate representation of older people (particularly \>75 years) in four trials done exclusively among people with heart failure[@bib17], [@bib18] or receiving renal dialysis,[@bib19], [@bib20] for whom statin therapy shows little or no benefit, we also examined the effects after exclusion of these trials.

Analyses included all randomised patients, irrespective of whether they received their allocated treatment (intention to treat). Estimates of the effects on disease rates within each trial were derived from the log-rank (o -- e) statistic and its variance (v) for first events. Meta-analyses were weighted by the absolute LDL cholesterol difference in that trial at 1 year (d mmol/L), and are reported as effects per 1·0 mmol/L reduction in LDL cholesterol.[@bib1], [@bib2], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16] In a meta-analysis of several trials, the log of the RR per 1·0 mmol/L was then calculated as S/V with variance 1/V (and hence, for example, with 95% CI of S/V ± 1·96 ÷√V), where S is the sum over all trials of d(o -- e) and V is the sum over all trials of d^2^v. We compared proportional risk reductions in different age subgroups by use of standard χ^2^ tests for heterogeneity when there were two groups, or trend when there were more than two groups.

To allow for multiple subdivisions of the data into subgroups, we present only summary RRs with 95% CIs; all other RRs are presented with 99% CIs. All analyses were done with SAS (version 9.3) and R (version 3.2.5).

Role of the funding source {#cesec50}
--------------------------

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The writing committee had full access to all the data in the study and takes final responsibility for its content and the decision to submit for publication.

Results {#cesec60}
=======

Individual participant data were provided by investigators or sponsors for 27 trials of statin therapy,[@bib2] and detailed summary data provided for one further trial,[@bib21] permitting meta-analyses of all 28 trials. Data were unavailable for four eligible trials (9264 participants), all of which exclusively enrolled people with known vascular disease.[@bib22], [@bib23], [@bib24], [@bib25]

In 23 trials, a statin-based regimen was compared with placebo or usual care (147 242 participants; median follow-up 4·8 years). In the other five trials, an intensive statin regimen was assessed against a standard statin regimen (39 612 participants; median follow-up 5·1 years).[@bib1] Across all 28 trials, the median follow-up duration was 4·9 years (range 2·0 to 7·0). 39 242 (21%) of 186 854 participants were aged 55 years or younger, 31 434 (17%) were 56--60 years, 37 764 (20%) were 61--65 years, 36 567 (20%) were 66--70 years, 27 314 (15%) were aged 71--75 years, and 14 483 (8%) were older than 75 years ([appendix](#sec1){ref-type="sec"}; age was unrecorded for 50 participants, none of whom had a major vascular event, died, or developed cancer during the trial).

We found significant differences in each of the measured baseline characteristics across the six age groups (p\<0·001 for all comparisons; [appendix](#sec1){ref-type="sec"}). Older participants were more likely to be female and to have heart failure or hypertension and were less likely to be current smokers. 2893 (20%) of patients older than 75 years compared with 6692 (4%) of those aged 75 years or younger were patients in heart failure trials, and 482 (3%) of patients older than 75 years compared with 3546 (2%) of those aged 75 years or younger were patients in renal dialysis trials ([table](#tbl1){ref-type="table"}). We observed a trend towards lower baseline LDL cholesterol concentrations with increasing age in the statin therapy versus control trials and---to a lesser extent---in the more intensive versus standard statin trials ([appendix](#sec1){ref-type="sec"}). Mean LDL cholesterol differences between treatment arms at one year (overall difference 1·08 mmol/L) were slightly smaller among older participants ([appendix](#sec1){ref-type="sec"}).TableBaseline characteristics**≤75 years (n=172 321)\>75 years (n=14 483)**Age (years)61·6 (8·0)78·8 (2·8)SexMale125 783 (73%)8476 (59%)Female46 538 (27%)6007 (41%)History of vascular disease96 088 (56%)8034 (55%)History of myocardial infarction59 654 (35%)4210 (29%)History of other symptomatic coronary heart disease61 767 (36%)4448 (31%)History of heart failure (New York Heart Association class II--IV)[\*](#tbl1fn1){ref-type="table-fn"}6692 (4%)2893 (20%)On dialysis[†](#tbl1fn2){ref-type="table-fn"}3546 (2%)482 (3%)History of diabetes31 919 (19%)2499 (17%)Current smoker35 701 (21%)1485 (10%)Treated hypertension82 213 (48%)8696 (60%)Systolic blood pressure (mm Hg)138·1 (19·5)143·4 (21·4)Diastolic blood pressure (mm Hg)81·2 (10·6)78·9 (10·8)Body--mass index (kg/m^2^)27·1 (24·6--30·1)26·3 (23·8--29·1)Total cholesterol (mmol/L)5·4 (1·0)5·1 (1·0)LDL cholesterol (mmol/L)3·3 (0·9)3·2 (0·8)HDL cholesterol (mmol/L)1·2 (0·3)1·3 (0·3)Triglycerides (mmol/L)1·6 (1·2--2·2)1·4 (1·0--1·9)Creatinine (μmol/L)[‡](#tbl1fn3){ref-type="table-fn"}94 (80--106)99 (88--117)[^2][^3][^4][^5]

Among all 28 trials, statin therapy or a more intensive statin regimen compared with control therapy or a less intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77--0·81) proportional reduction in the risk of a first major vascular event per 1·0 mmol/L reduction in LDL cholesterol. We found independently significant risk reductions in each of the age groups considered, including among patients older than 75 years at the start of treatment ([figure 1](#fig1){ref-type="fig"}). Although proportional reductions in major vascular events diminished slightly with increasing age, this trend was not statistically significant (p~trend~=0·06; [figure 1](#fig1){ref-type="fig"}). Previous studies have found that statin therapy does not reduce the rate of major vascular events among patients with moderate or severe heart failure or who are undergoing dialysis for renal failure[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] (p~heterogeneity~\<0·0001; [figure 2](#fig2){ref-type="fig"}). A disproportionate number of patients with heart failure or dialysis were in the older age groups of our overall meta-analysis population, which could confound comparisons between the effects of statin therapy by age. In exploratory analyses, after exclusion of 13 613 (7%) patients from four trials restricted to patients with heart failure or undergoing dialysis,[@bib17], [@bib18], [@bib19], [@bib20] the non-significant trend towards smaller proportional reductions in major vascular events with increasing age was diminished (p~trend~=0·3; [figure 1](#fig1){ref-type="fig"}). These patterns were unchanged after adjustment for sex, diabetes, hypertension, smoking, previous cardiovascular disease status, body--mass index (BMI), and renal function (adjusted p~trend~=0·06 in 27 trials with individual participant data; p=0·4 after exclusion of four trials that exclusively included participants with heart failure or on dialysis).Figure 1Effects on major vascular events per mmol/L reduction in LDL cholesterol by age at randomisationAll studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.Figure 2Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and particular trial populationsData from participants with missing baseline data included in the totals. RR=rate ratio.

Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73--0·79) proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol. We found a statistically significant trend towards smaller proportional reductions in major coronary events with increasing age (p~trend~=0·009; [figure 3](#fig3){ref-type="fig"}), which remained significant after exclusion of the heart failure and dialysis trials (p~trend~=0·01; [appendix](#sec1){ref-type="sec"}). These patterns were unchanged after adjustment for sex, diabetes, hypertension, smoking, previous cardiovascular disease status, BMI, and renal function (adjusted p~trend~=0·008 in 27 trials with individual participant data; p=0·012 after exclusion of four trials that exclusively included participants with heart failure or on dialysis). Nevertheless, there was still a significant reduction in major coronary events among all patients older than 75 years ([figure 3](#fig3){ref-type="fig"}). When we compared patients aged 75 years or younger with patients older than 75 years, we found no significant differences between the proportional effects on major coronary events, or on non-fatal myocardial infarctions and coronary deaths considered separately (with or without exclusion of the heart failure or dialysis trials; [appendix](#sec1){ref-type="sec"}).Figure 3Effects on components of major vascular events per mmol/L reduction in LDL cholesterol in all studies, by age at randomisationData from participants with missing baseline data included in the totals. RR=rate ratio.

Overall, we observed a 25% (RR 0·75, 95% CI 0·73--0·78) proportional reduction in the risk of coronary revascularisation procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which did not differ significantly across age categories (p~trend~=0·6), although we found no apparent effect on the relatively small number of procedures done among patients older than 75 years ([figure 3](#fig3){ref-type="fig"}; [appendix](#sec1){ref-type="sec"}). Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80--0·89) did not differ significantly by age group (p~trend~=0·7; [figure 3](#fig3){ref-type="fig"}).

Among participants with known vascular disease at study entry, proportional reductions in major vascular events were similar across age groups, regardless of whether heart failure and dialysis trials were included or excluded (p~trend~=0·2 when these trials were included, p~trend~=0·9 when these trials were excluded; [figure 4](#fig4){ref-type="fig"}; [appendix](#sec1){ref-type="sec"}). However, among participants with no history of vascular disease, we observed a significant trend towards smaller proportional risk reductions with increasing age (p~trend~=0·05; [figure 4](#fig4){ref-type="fig"}), which persisted after exclusion of the heart failure and dialysis trials (p~trend~=0·03; [appendix](#sec1){ref-type="sec"}).Figure 4Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and by previous vascular diseaseData from participants with missing baseline data included in the totals. RR=rate ratio.

Overall, we found a 12% (RR 0·88, 95% CI 0·85--0·91) proportional reduction in vascular mortality per 1·0 mmol/L reduction in LDL cholesterol, with a trend towards smaller proportional reductions with older age (p~trend~=0·004; [figure 5](#fig5){ref-type="fig"}). However, 1014 (53%) of 1906 vascular deaths among people older than 75 years occurred in the four heart failure or dialysis trials. After exclusion of these trials, we observed no apparent trend towards smaller proportional reductions in vascular mortality with older age (p~trend~=0·2, [figure 5](#fig5){ref-type="fig"}). We found no effect of statin therapy on all non-vascular causes of death (RR 0·96, 95% CI 0·92--1·01) irrespective of age group (p~trend~=0·7; [appendix](#sec1){ref-type="sec"}). We also found no effects on deaths due to cancer or on the larger numbers of incident cancer cases, overall or by age ([appendix](#sec1){ref-type="sec"}). Consequently, when the beneficial effect on vascular mortality and the absence of effect on non-vascular mortality were combined, we observed a significant reduction in all-cause mortality (RR 0·91, 95% CI 0·88--0.93; [appendix](#sec1){ref-type="sec"}). We also found a trend towards smaller proportional reductions in all-cause mortality with increasing age (p~trend~=0·04; [appendix](#sec1){ref-type="sec"}), but this did not persist after exclusion of the heart failure and dialysis trials (p~trend~=0·1, [appendix](#sec1){ref-type="sec"}).Figure 5Effects on vascular death per mmol/L reduction in LDL cholesterol, subdivided by age at randomisationAll studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.

Discussion {#cesec70}
==========

Individual randomised trials of statin therapy have previously reported significant cardiovascular risk reductions among participants older than 65 years but younger than 70 years at the time of randomisation (who were therefore aged \>70--75 years at the end of a median of 5 years of scheduled treatment).[@bib26], [@bib27], [@bib28], [@bib29], [@bib30] Meta-analyses among older people have consistently reported evidence for beneficial effects in secondary prevention, but the evidence has been less clear for primary prevention.[@bib31], [@bib32], [@bib33], [@bib34] Availability of individual participant data in the CTT Collaboration database has permitted more detailed assessment of the effects of statin therapy at different ages.

In our meta-analysis of data from 28 trials among 186 854 people (with 14 483 \[8%\] older than 75 years at randomisation), we found slightly smaller proportional risk reductions in major vascular events (p~trend~=0·06) and vascular deaths (p~trend~=0·004) with increasing age. The exclusion criteria for 24 trials incorporated at least one of the following: a history of heart failure, poor ejection fraction, poor prognosis (other than from atherosclerotic disease), or the requirement for renal dialysis. However, two trials exclusively enrolled patients with moderate to severe (New York Heart Association Class II--IV) heart failure[@bib17], [@bib18] and two exclusively enrolled patients with end-stage renal disease requiring dialysis.[@bib19], [@bib20] Statin therapy has not been found to reduce the risk of major vascular events or vascular deaths in either of these patient populations,[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] and consequently is not recommended for such patients in the absence of other indications.[@bib10], [@bib35], [@bib36] Therefore, we did exploratory analyses that excluded these four trials[@bib17], [@bib18], [@bib19], [@bib20] to assess their contribution to the observed trends towards smaller relative reductions with increasing age. Among people without heart or renal failure, we found little evidence of any diminution of benefit with increasing age on major vascular events (p~trend~=0·3) or on vascular death (p~trend~=0·2).

Proportional reductions in major vascular events were similar irrespective of age among patients with a history of vascular disease (ie, secondary prevention), but we observed a trend towards smaller proportional risk reductions in those with no known vascular disease (ie, primary prevention), with no independently significant reductions in either of the two age groups including patients older than 70 years. Among patients older than 70 years, only around a fifth of the major vascular events occurred in those with no history of vascular disease, and this relative paucity of evidence has led to further primary prevention trials among older individuals. For example, the STAREE trial[@bib37] aims to assess the effects of atorvastatin 40 mg daily in 18 000 primary prevention patients aged 70 years or older at the time of recruitment.

We observed a trend towards smaller proportional reductions in major coronary events (p~trend~=0·009) with increasing age, although a significant reduction remained among patients older than 75 years at randomisation. The reasons underlying this trend are unclear. Age-related factors---such as altered pharmacokinetics and pharmacodynamics and an increased risk of drug interactions in the setting of polypharmacy[@bib38]---would be expected to influence absolute LDL cholesterol reductions from therapy, but these did not differ materially by age. This trend might reflect a reduced capacity for statins to impact on advanced atherosclerotic plaques, greater diagnostic uncertainty at older ages (eg, difficulty separating myocardial infarctions due to unstable atherosclerosis from supply--demand imbalances that occur with other illnesses), and poorer long-term adherence to the assigned study treatment among older people (since our weighted analyses are based on 1 year cholesterol differences). We observed no trends towards smaller proportional reductions in coronary revascularisation procedures or strokes with increasing age, but too few such events occurred among patients older than 75 for us to assess the effects on these outcomes directly. Statin therapy definitely decreases the overall risk of ischaemic stroke and any stroke, but might increase the risk of haemorrhagic stroke.[@bib14] Individual participant data were not available from one eligible trial[@bib22] in which a large number of strokes (especially haemorrhagic) occurred, and we cannot reliably comment on the relevance of age to the effects of statin therapy on stroke subtypes.

There is a paucity of information on the effects of statins on mortality in people at low risk of vascular disease, and very large trials (eg, the ongoing STAREE trial[@bib37]) would be needed to provide direct evidence of a mortality reduction among older people in primary prevention. However, our overall analyses in a combined primary and secondary prevention population indicate that the proportional reductions in vascular mortality are similar irrespective of age. We have previously shown that statin therapy does not increase the incidence of cancer[@bib15] (as had been suggested[@bib8]) or of non-vascular causes of death.[@bib14] Consequently, given the similar proportional reductions in vascular mortality in both primary and secondary prevention settings, and the complete absence of effect of statin therapy on non-vascular mortality, reductions in total mortality would be expected in both clinical settings.

Statins have been estimated to increase the risk of myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase) typically by one case per 10 000 patients treated with statins per year,[@bib9] but this risk can be increased by drug interactions and major comorbidities that are more common in older people.[@bib39] A meta-analysis[@bib40] of published data for participants older than 65 years at randomisation in statin trials reported no increased risk of less severe muscle-related adverse events. The CTT Collaboration is undertaking a prespecified analysis of reported adverse events in statin trials from original trial records,[@bib41] including examining whether age directly influences the small increase in risk of diabetes,[@bib42], [@bib43] and whether statins adversely influence cognition (noting that no excess risks have been identified in any large randomised trials[@bib29], [@bib30], [@bib44], [@bib45]).

The selection criteria used among the 28 trials contributing to this meta-analysis, and differences in when they were conducted, mean that the absolute risk of major vascular events and mortality in our overall study population is not likely to be representative of any contemporary population. Therefore, we have not produced estimates of the absolute effects of statin therapy directly from the numbers of events observed in these trials. By contrast, the proportional effects observed in this meta-analysis are likely to be widely generalisable. Consequently, as the proportional reductions in major vascular events appeared to diminish only slightly (if at all) with increasing age, while untreated absolute risks of major vascular events in the general population increase exponentially with age, the absolute benefits of a given absolute reduction in LDL cholesterol with statin therapy would be expected to be substantially greater among older individuals. For example, in the primary prevention setting, two individuals aged 63 years and 78 years with otherwise identical risk factors might have projected major vascular event rates of 2·5% versus 4·0% per year, respectively. Reducing those risks by a fifth with a 1·0 mmol/L LDL cholesterol reduction would prevent first major vascular events from occurring each year in 50 individuals aged 63 years and 80 individuals aged 78 years per 10 000 people treated.

In conclusion, statin therapy produces significant reductions in major vascular events, irrespective of age. There is less definitive direct evidence of benefit in the primary prevention setting among patients older than 75 years, but evidence supports the use of statin therapy in older people considered to have a sufficiently high risk of occlusive vascular events.
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[^1]: Members are listed at the end of the Article

[^2]: Data are mean SD, n (%), or median (IQR). HOPE-3 participant data for body-mass index (mean 27·2 kg/m^2^ \[SD 4·8\] among participants ≤75 years and 26·1 kg/m^2^ \[4·8\] among participants \>75 years), triglycerides (1·7 mmol/L \[1·1\] among participants ≤75 years and 1·6 mmol/L \[0·9\] among participants \>75 years), and creatinine (79 μmol/L \[19\] among participants ≤75 years and 82 μmol/L \[20\] among participants \>75 years) not included. 50 participants with missing age (49 from MEGA and one from A to Z) were excluded.

[^3]: All participants from GISSI-HF and CORONA trials only.

[^4]: All participants from 4D and AURORA trials.

[^5]: Excludes participants on dialysis at randomisation (ie, participants from 4D and AURORA).
